menu
    • menu
    [{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sensidose","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"15","companyTruncated":"Sensidose \/ Navamedic"},{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sensidose","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"15","companyTruncated":"Sensidose \/ Navamedic"}]

    Find Clinical Drug Pipeline Developments & Deals by Sensidose

    Menu

    Sensidose

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sensidose

                            Sweden arrow
                            Organic Process R&D
                            Not Confirmed

                            Sensidose

                            Sweden arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etilevodopa,Carbidopa

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Navamedic

                            Deal Size : $9.3 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Navamedic ASA: Amended Cash Offer to Acquire Sensidose AB And Acquisition of Shares in Sensidose AB

                            Details : Through the acquisition, Navamedic will broaden its product portfolio, including Flexilev, containing two active substances, levodopa and carbidopa and to support patients suffering from medical conditions, such as Parkinson's disease.

                            Product Name : Flexilev

                            Product Type : Miscellaneous

                            Upfront Cash : $9.3 million

                            April 24, 2023

                            Lead Product(s) : Etilevodopa,Carbidopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Navamedic

                            Deal Size : $9.3 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sensidose

                            Sweden arrow
                            Organic Process R&D
                            Not Confirmed

                            Sensidose

                            Sweden arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etilevodopa,Carbidopa

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Navamedic

                            Deal Size : $7.2 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Navamedic ASA: Recommended Cash Offer to Acquire Sensidose for Approximately SEK 75 Million

                            Details : Through the acquisition, Navamedic will broaden its product portfolio and to support patients suffering from medical conditions, such as Parkinson's disease, including Flexilev, containing two active substances, levodopa and carbidopa.

                            Product Name : Flexilev

                            Product Type : Miscellaneous

                            Upfront Cash : $7.2 million

                            March 29, 2023

                            Lead Product(s) : Etilevodopa,Carbidopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Navamedic

                            Deal Size : $7.2 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth